Atara Biotherapeutics (ATRA) Given Media Sentiment Score of 0.04

Headlines about Atara Biotherapeutics (NASDAQ:ATRA) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Atara Biotherapeutics earned a news impact score of 0.04 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.9601776772791 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the headlines that may have impacted Accern’s analysis:

Atara Biotherapeutics (NASDAQ ATRA) opened at $18.50 on Friday. The stock has a market capitalization of $695.53, a PE ratio of -5.33 and a beta of 1.27. Atara Biotherapeutics has a fifty-two week low of $11.80 and a fifty-two week high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.05). research analysts anticipate that Atara Biotherapeutics will post -4 earnings per share for the current year.

Several research analysts recently weighed in on the company. Citigroup upgraded Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price on the stock in a research note on Wednesday. ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a research note on Thursday, November 9th. Jefferies Group reaffirmed a “buy” rating and set a $30.00 price target on shares of Atara Biotherapeutics in a research report on Thursday, October 5th. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $20.00 price target on shares of Atara Biotherapeutics in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $26.00.

In other news, CEO Isaac E. Ciechanover sold 2,200 shares of the business’s stock in a transaction dated Wednesday, October 11th. The stock was sold at an average price of $15.25, for a total value of $33,550.00. Following the completion of the transaction, the chief executive officer now owns 737,767 shares of the company’s stock, valued at approximately $11,250,946.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Christopher Haqq sold 6,000 shares of the business’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $14.35, for a total value of $86,100.00. The disclosure for this sale can be found here. In the last three months, insiders sold 128,388 shares of company stock valued at $2,294,572. Insiders own 16.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Atara Biotherapeutics (ATRA) Given Media Sentiment Score of 0.04” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2018/01/07/atara-biotherapeutics-atra-given-media-sentiment-score-of-0-04.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit